Use of availability CD 24 for immuno related adverse cases of cancer therapy

摘要

The present invention is for the treatment of CD 24 protein of immune related adverse event (Irae) related to cancer immunotherapy.Treatment of immuno related adverse cases (iraes) associated with cancer immunotherapy, mitigation, minimization or prevention methods are provided in this article.Irae may be diarrhea or other intestinal disorders, pure hemopoiesis, small red blood cell anemia, cysts, autoimmune nephritis, pneumonia, myocarditis, pericarditis, endocrinopathy, Addison's disease, hypogonadism, shaugren's syndrome or first diabetes.CD24 proteins can contain mature human CD24 or variants.